EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
2.990
-0.150 (-4.78%)
At close: Oct 16, 2026, 4:00 PM EDT
2.990
0.00 (0.00%)
Pre-market: Oct 19, 2026, 5:47 AM EDT
EyePoint Revenue
EyePoint had revenue of $507.00K in the quarter ending June 30, 2026, a decrease of -90.49%. This brings the company's revenue in the last twelve months to $2.79M, down -94.63% year-over-year. In the year 2025, EyePoint had annual revenue of $31.37M, down -27.50%. That makes EyePoint the 41,629th largest company in the world by revenue and 5,620th in the United States.
Revenue (ttm)
$2.79M
Revenue Growth
-94.63%
P/S Ratio
92.46
Revenue / Employee
$13,028
Employees
214
Market Cap
257.77M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.37M | -11.90M | -27.50% |
| Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
| Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
| Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
| Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
| Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
| Dec 31, 2019 | 20.37M | 15.79M | 345.53% |
| Dec 31, 2018 | 4.57M | 1.61M | 54.37% |
| Jun 30, 2018 | 2.96M | -4.58M | -60.72% |
| Jun 30, 2017 | 7.54M | 5.92M | 365.37% |
| Jun 30, 2016 | 1.62M | -24.95M | -93.90% |
| Jun 30, 2015 | 26.57M | 23.09M | 664.90% |
| Jun 30, 2014 | 3.47M | 1.33M | 62.06% |
| Jun 30, 2013 | 2.14M | -1.38M | -39.22% |
| Jun 30, 2012 | 3.53M | -1.44M | -28.98% |
| Jun 30, 2011 | 4.97M | -18.09M | -78.46% |
| Jun 30, 2010 | 23.05M | 10.89M | 89.55% |
| Jun 30, 2009 | 12.16M | 8.69M | 249.88% |
| Jun 30, 2008 | 3.48M | 1.69M | 94.73% |
| Jun 30, 2007 | 1.79M | 749.00K | 72.30% |
| Jun 30, 2006 | 1.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Century Therapeutics | 109.16M |
| Clinuvel Pharmaceuticals | 65.05M |
| Abeona Therapeutics | 25.52M |
| X4 Pharmaceuticals | 15.85M |
| Lineage Cell Therapeutics | 13.08M |
| Ocugen | 4.58M |
| Palisade Bio | 500.00K |
EYPT News
- 9 minutes ago - EyePoint reports LUCIA trial did not achieve primary endpoint - TheFly
- 27 days ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch
- 4 weeks ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - EyePoint Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 5 weeks ago - EyePoint Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 weeks ago - EyePoint Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 5 weeks ago - EyePoint Slides: Corporate presentation - Filings
- 6 weeks ago - EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - GlobeNewsWire